Oxamflatin is a novel antitumor compound that inhibits mammalian histone deacetylase
about
Che-1 arrests human colon carcinoma cell proliferation by displacing HDAC1 from the p21WAF1/CIP1 promoterHistone deacetylases (HDACs): characterization of the classical HDAC familyHistone deacetylase inhibitors induce remission in transgenic models of therapy-resistant acute promyelocytic leukemiaHistone deacetylase 4 associates with extracellular signal-regulated kinases 1 and 2, and its cellular localization is regulated by oncogenic RasThe histone deacetylase inhibitor Trichostatin A modulates CD4+ T cell responsesMechanisms of Histone Deacetylase Inhibitor-Regulated Gene Expression in Cancer CellsBioactive heterocycles containing endocyclic N-hydroxy groupsHistone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cellsPreclinical studies of chemotherapy using histone deacetylase inhibitors in endometrial cancerSelective induction of cyclin-dependent kinase inhibitors and their roles in cell cycle arrest caused by trichostatin A, an inhibitor of histone deacetylase.Histone Deacetylase Inhibitor M344 Inhibits Cell Proliferation and Induces Apoptosis in Human THP-1 Leukemia Cells.Effects of histone deacetylase inhibitor oxamflatin on in vitro porcine somatic cell nuclear transfer embryos.Oxamflatin significantly improves nuclear reprogramming, blastocyst quality, and in vitro development of bovine SCNT embryos.Histone deacetylase inhibitors: novel anticancer agents.Acetylation of core histones in response to HDAC inhibitors is diminished in mitotic HeLa cells.Histone modification enzymes: novel targets for cancer drugs.Histone deacetylase inhibitors in the treatment of hematological malignancies and solid tumors.Potent histone deacetylase inhibitors built from trichostatin A and cyclic tetrapeptide antibiotics including trapoxin.The tumor suppressor p53 and histone deacetylase 1 are antagonistic regulators of the cyclin-dependent kinase inhibitor p21/WAF1/CIP1 gene.Histone deacetylase inhibitors: from target to clinical trials.Augmenting antitumor immune responses with epigenetic modifying agents.Signal transduction mediated by the Ras/Raf/MEK/ERK pathway from cytokine receptors to transcription factors: potential targeting for therapeutic intervention.Modified fatty acids and their possible therapeutic targets in malignant diseases.Paraquat induces epigenetic changes by promoting histone acetylation in cell culture models of dopaminergic degeneration.Histone deacetylase inhibitors for treatment of hepatocellular carcinoma.P21-dependent g(1)arrest with downregulation of cyclin D1 and upregulation of cyclin E by the histone deacetylase inhibitor FR901228Epigenetics in Friedreich's Ataxia: Challenges and Opportunities for Therapy.HDAC1 inhibition by maspin abrogates epigenetic silencing of glutathione S-transferase pi in prostate carcinoma cells.Nonsteroidal anti-inflammatory drug-activated gene (NAG-1/GDF15) expression is increased by the histone deacetylase inhibitor trichostatin AEpigenetics and dermatological disease.Epigenetic mechanisms of regulation of Foxp3 expression.Histone deacetylase inhibitors (HDACIs). Structure--activity relationships: history and new QSAR perspectives.Epigenetic-based therapies for Friedreich ataxia.The effect of oxamflatin on the E-cadherin expression in gastric cancer cell line.Chemical and structural biology of protein lysine deacetylasesValproic acid inhibits proliferation of EB virus-infected natural killer cells.Histone deacetylase inhibitors induce mitochondrial elongation.Histonedeacetylase inhibitor Oxamflatin increase HIV-1 transcription by inducing histone modification in latently infected cells.Histone deacetylase inhibitor NVP-LAQ824 has significant activity against myeloid leukemia cells in vitro and in vivo.Histone deacetylase inhibitors specifically kill nonproliferating tumour cells.
P2860
Q24307441-7FBED8E7-5E8C-4AEF-8FF2-398B930240E6Q24535587-0ABBD358-A75C-4097-9BAE-D3CA024487DAQ24671020-369E9A7F-2E66-494B-99EF-59EFBD613C0FQ24673033-110EB557-076E-465A-9742-6AA582E5AC87Q24796904-5C97A17B-235B-4BA9-8FA5-1AE4BFA43EFFQ27015931-63F81A81-128F-4940-8B07-256CC5911D62Q27025241-30B52E65-82A7-46B4-883A-C13512D68A7DQ28142463-E5B294C3-3CAC-43C9-9BDC-2C3583BC0A30Q33651762-BADFCB51-862F-490D-A780-AF4C122AAEB3Q33833422-4FB4F252-314C-429B-83B5-5753C2E45434Q33893161-E5293128-AD3A-4A0E-875C-4914656C5367Q33974955-1C750290-FC6E-47FF-B56A-8F315FF9E5B8Q34017629-7905B757-40FD-4A8D-A72B-B6DBAAD63766Q34119504-29F42DFE-9A70-4E29-8ABD-DF828656BAB7Q34122502-64490442-E7CE-4087-813F-919B205B1177Q34322087-A20D7040-5CFE-4655-9EFA-7E1566130B52Q34416994-4D600D0A-760A-4469-A3DE-6B7336AD428CQ34584029-8B5F7643-F6A0-4F13-B44E-5A80F176AB33Q34888585-8FD2038C-FDE5-44EB-8C17-4EF1DC5C1B87Q35011880-732EC172-0E04-4428-B22B-0233DF3F364AQ35048054-36C82512-8277-48FB-93FB-0D60C08DD2D6Q35166852-982E4E7F-ACE3-4666-8166-2B0BE4867F02Q35537914-57C886B8-67DB-4CF6-A5C4-A697999EAADFQ36123405-406EB385-5A21-456B-9DD3-448CAFF13367Q36237743-6E617D47-7274-46D2-BCDC-DA2DE51D1778Q36621938-D530585D-7DFE-4C43-BB38-C678CC4342D3Q36663928-0D4B64D2-60EE-4CE2-A63D-6F3C97657E3FQ36728257-C0F0E652-9320-4562-860C-CFA245E8F492Q36981029-3013B33C-033E-4973-832D-6752EB9EBF56Q37346201-07E1B447-774A-4886-8A19-18B6BECC413BQ37412329-D07DB2F0-48EF-491E-96D0-F4F9DDD43CA9Q37693855-98F1C082-E31A-43C5-83EC-D2927957F1E4Q38219414-AFD78D07-59D1-4148-90CA-25DE33228542Q38739161-F81F05D3-9C16-4676-976E-FFE1AB4E1CC4Q39299912-D996C459-3268-4BCE-9DE8-605DE5394F33Q39337509-800D8A5F-ABF3-41D6-9F8A-D9F9738B49CFQ39471991-77D682B1-D48F-4F64-BF4B-776A30A99D89Q39616690-DF3C153D-0162-4693-8E67-6A90336853F7Q40501526-E415AEE8-9DFD-47CD-B351-375C8E233E47Q40538874-ABD51790-F107-4A30-A6AA-5ADBB4290DAF
P2860
Oxamflatin is a novel antitumor compound that inhibits mammalian histone deacetylase
description
im April 1999 veröffentlichter wissenschaftlicher Artikel
@de
wetenschappelijk artikel
@nl
наукова стаття, опублікована у квітні 1999
@uk
name
Oxamflatin is a novel antitumor compound that inhibits mammalian histone deacetylase
@en
Oxamflatin is a novel antitumor compound that inhibits mammalian histone deacetylase
@nl
type
label
Oxamflatin is a novel antitumor compound that inhibits mammalian histone deacetylase
@en
Oxamflatin is a novel antitumor compound that inhibits mammalian histone deacetylase
@nl
prefLabel
Oxamflatin is a novel antitumor compound that inhibits mammalian histone deacetylase
@en
Oxamflatin is a novel antitumor compound that inhibits mammalian histone deacetylase
@nl
P2093
P2860
P356
P1433
P1476
Oxamflatin is a novel antitumor compound that inhibits mammalian histone deacetylase
@en
P2093
Kenji Sugita
Kun-Hyung Lee
Sueharu Horinouchi
Young Bae Kim
P2860
P2888
P304
P356
10.1038/SJ.ONC.1202564
P407
P577
1999-04-01T00:00:00Z